Thirdly, previous studies indicated that EGFR mutations were associated with low response rates to PD-1 blockade treatment among patients with NSCLC; in some cases, inhibition of checkpoint blockade even increased the rate of tumor growth considerably [31–33]. This evidence concerns the gene EGFR and neoplasm.